Canada grants interim clearance to Eli Lilly’s anti-COVID-19 drug | TBEN News


Canada has granted provisional authorization for Eli Lilly’s antibody drug for the treatment of COVID-19 in patients who are not hospitalized but who are at risk of serious illness due to their age or other conditions, said Friday the drug maker.

The news comes weeks after the treatment, bamlanivimab, was approved for emergency use in the United States by the Food and Drug Administration to help newly diagnosed high-risk patients avoid hospitalization.

ALSO READ  Put face masks to the test; The Fight for Airline Refunds: TBEN Market Cheat Sheet | TBEN News

Bamlanivimab was developed in partnership with Canadian biotechnology company AbCellera.

The Health Canada clearance was based on a clinical study in patients with mild to moderate COVID-19, where patients treated with bamlanivimab had a viral load and reduced symptom and hospitalization rates.

The drug is a monoclonal antibody – a widely used class of biotech drugs – which in this case is a fabricated copy of an antibody that the human body creates to fight infections.

ALSO READ  Stuck in a hotel during a Christmas pandemic, the inhabitants of Neskantaga await the end of the water crisis | TBEN News

“This authorization in Canada contributes to our goal of making bamlanivimab available to patients who need it around the world and is a testament to the close collaboration between industry and governments to bring COVID-19 drugs to the people most. quickly possible, ”David A. Ricks, Chairman and CEO of Lilly, said in a statement released Friday.

WATCH | How well will COVID-19 vaccines work in the real world?

Infectious disease specialists are answering questions about COVID-19 vaccines, including whether clinical trial results will hold up in the real world. 6:49

ALSO READ  US Secretary of Defense Mark Esper Sacked, Trump Twitter Ad | TBEN News


Please enter your comment!
Please enter your name here